2.63
price up icon1.54%   0.04
pre-market  プレマーケット:  2.67   0.04   +1.52%
loading
前日終値:
$2.59
開ける:
$2.62
24時間の取引高:
2.53M
Relative Volume:
1.39
時価総額:
$288.71M
収益:
-
当期純損益:
$-209.38M
株価収益率:
-1.4013
EPS:
-1.8768
ネットキャッシュフロー:
$-179.81M
1週間 パフォーマンス:
-12.91%
1か月 パフォーマンス:
-29.30%
6か月 パフォーマンス:
-26.54%
1年 パフォーマンス:
-19.33%
1日の値動き範囲:
Value
$2.5501
$2.73
1週間の範囲:
Value
$2.51
$3.025
52週間の値動き範囲:
Value
$2.51
$5.45

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name
名前
Rocket Pharmaceuticals Inc
Name
セクター
Healthcare (1062)
Name
電話
646-440-9100
Name
住所
350 FIFTH AVENUE, NEW YORK, NY
Name
職員
202
Name
Twitter
@rocketpharma
Name
次回の収益日
2026-11-05
Name
最新のSEC提出書
Name
RCKT's Discussions on Twitter

Compare RCKT vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
RCKT icon
RCKT
Rocket Pharmaceuticals Inc
2.63 284.87M 0 -209.38M -179.81M -1.8768
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
522.81 133.37B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
758.27 81.13B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
192.57 79.40B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
958.91 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
205.26 43.93B 742.00K -1.37B -1.07B -7.0731

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-11-18 ダウングレード JP Morgan Neutral → Underweight
2025-08-20 アップグレード BofA Securities Neutral → Buy
2025-07-25 ダウングレード BofA Securities Buy → Neutral
2025-05-30 ダウングレード Evercore ISI Outperform → In-line
2025-05-28 ダウングレード Goldman Neutral → Sell
2025-05-28 ダウングレード JP Morgan Overweight → Neutral
2025-05-28 ダウングレード Jefferies Buy → Hold
2025-05-28 ダウングレード Leerink Partners Outperform → Market Perform
2025-05-28 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-05-27 ダウングレード Needham Buy → Hold
2025-05-27 ダウングレード TD Cowen Buy → Hold
2025-03-12 開始されました BMO Capital Markets Outperform
2024-12-30 開始されました Wedbush Outperform
2024-12-18 開始されました Jefferies Buy
2024-10-16 開始されました Scotiabank Sector Outperform
2024-04-02 開始されました Goldman Neutral
2023-10-24 開始されました Cantor Fitzgerald Overweight
2023-02-01 開始されました Morgan Stanley Overweight
2022-11-08 開始されました Canaccord Genuity Buy
2022-11-01 開始されました BTIG Research Buy
2022-07-08 開始されました Raymond James Outperform
2021-10-20 再開されました Cowen Outperform
2021-03-02 開始されました Stifel Buy
2021-02-18 開始されました Needham Buy
2020-12-16 開始されました UBS Buy
2020-12-08 ダウングレード Oppenheimer Outperform → Perform
2020-07-02 開始されました JP Morgan Overweight
2020-06-25 再開されました BofA/Merrill Buy
2020-06-01 再開されました Oppenheimer Outperform
2019-11-06 開始されました Chardan Capital Markets Buy
2019-09-26 開始されました Piper Jaffray Overweight
2019-04-23 開始されました Robert W. Baird Outperform
2019-03-15 開始されました BofA/Merrill Buy
2019-02-05 開始されました Oppenheimer Outperform
2018-09-13 開始されました Ladenburg Thalmann Buy
2018-07-10 開始されました William Blair Outperform
すべてを表示

Rocket Pharmaceuticals Inc (RCKT) 最新ニュース

pulisher
Sep 26, 2026

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits

Sep 26, 2026
pulisher
Sep 24, 2026

Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment - streetwisereports.com

Sep 24, 2026
pulisher
Sep 24, 2026

Rocket Pharmaceuticals, Inc. (RCKT) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 24, 2026
pulisher
Sep 22, 2026

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns? - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Rocket Pharmaceuticals stock holds focus on clinical milestones - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 17, 2026

Have Insiders Sold Rocket Pharmaceuticals Shares Recently? - simplywall.st

Sep 17, 2026
pulisher
Sep 16, 2026

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease - The Globe and Mail

Sep 16, 2026
pulisher
Sep 16, 2026

Needham Upgrade Boosts Rocket Pharmaceuticals (RCKT) on FDA Tria - GuruFocus

Sep 16, 2026
pulisher
Sep 16, 2026

Rocket Pharma stock upgraded at Needham (RCKT:NASDAQ) - Seeking Alpha

Sep 16, 2026
pulisher
Sep 16, 2026

Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo

Sep 16, 2026
pulisher
Sep 16, 2026

RCKT Reiterates by Wedbush -- Price Target Maintained at $15 - GuruFocus

Sep 16, 2026
pulisher
Sep 16, 2026

Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock - Yahoo Finance

Sep 16, 2026
pulisher
Sep 16, 2026

Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy After FDA Trial Design Approval - GuruFocus

Sep 16, 2026
pulisher
Sep 16, 2026

Rocket Pharmaceuticals general counsel sells $256,463 in RCKT shares By Investing.com - Investing.com South Africa

Sep 16, 2026
pulisher
Sep 15, 2026

Rocket Pharmaceuticals (RCKT) counsel sells shares to cover RSU tax bill - stocktitan.net

Sep 15, 2026
pulisher
Sep 15, 2026

Former Rocket Pharmaceuticals (RCKT) executive plans stock sale tied to equity award taxes - Stock Titan

Sep 15, 2026
pulisher
Sep 15, 2026

Rocket Pharma Jumps as FDA Backs 12-Patient Pivotal Plan for Danon Gene Therapy - finance.biggo.com

Sep 15, 2026
pulisher
Sep 15, 2026

Rocket Pharma gets FDA alignment on Danon disease trial By Investing.com - Investing.com Nigeria

Sep 15, 2026
pulisher
Sep 15, 2026

RCKT Maintained by Chardan Capital -- Price Target Stays at $11. - GuruFocus

Sep 15, 2026
pulisher
Sep 15, 2026

Rocket Pharmaceuticals Secures FDA Agreement on RP-A501 Phase 2 Trial for Danon Disease - Kalkine Media

Sep 15, 2026
pulisher
Sep 15, 2026

Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial - Yahoo Finance

Sep 15, 2026
pulisher
Sep 15, 2026

Why is Rocket Pharmaceuticals stock down 5% today? By Investing.com - Investing.com Canada

Sep 15, 2026
pulisher
Sep 15, 2026

Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights - Yahoo Finance

Sep 15, 2026
pulisher
Sep 15, 2026

Form 8K Rocket Pharmaceuticals Inc For: 15 September By Investing.com - Investing.com Nigeria

Sep 15, 2026
pulisher
Sep 15, 2026

Rocket Pharmaceuticals (RCKT) Advances Phase 2 Trial with FDA Ag - GuruFocus

Sep 15, 2026
pulisher
Sep 15, 2026

Rocket Pharmaceuticals Says FDA Confirms Path to Complete Phase 2 Danon Disease Trial - marketscreener.com

Sep 15, 2026
pulisher
Sep 15, 2026

Rocket Pharma gets FDA alignment on Danon disease trial - Investing.com

Sep 15, 2026
pulisher
Sep 15, 2026

RCKT 8-K FilingsRocket Pharmaceuticals, Inc. SEC 8-K - Stock Titan

Sep 15, 2026
pulisher
Sep 15, 2026

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease - businesswire.com

Sep 15, 2026
pulisher
Sep 14, 2026

Former Rocket Pharmaceuticals (RCKT) officer plans to sell 6,857 shares under an SEC trading rule - Stock Titan

Sep 14, 2026
pulisher
Sep 11, 2026

Rocket Pharma (RCKT) executive plans sale of 75K shares tied to vested stock taxes - Stock Titan

Sep 11, 2026
pulisher
Sep 11, 2026

Former Rocket Pharma (NASDAQ: RCKT) exec plans stock sale - Stock Titan

Sep 11, 2026
pulisher
Sep 11, 2026

Rocket Pharmaceuticals Inc. (RCKT) Key Financial Ratios – Valuation, Profitability & More - Value Research

Sep 11, 2026
pulisher
Sep 10, 2026

Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus By Investing.com - Investing.com Canada

Sep 10, 2026
pulisher
Sep 10, 2026

Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus - Investing.com

Sep 10, 2026
pulisher
Sep 09, 2026

Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Sep 09, 2026
pulisher
Sep 04, 2026

RCKT News | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill

Sep 04, 2026
pulisher
Sep 03, 2026

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance

Sep 03, 2026
pulisher
Sep 02, 2026

Rocket Pharma (NASDAQ: RCKT) to pull 2026 warrant listing - Stock Titan

Sep 02, 2026
pulisher
Sep 01, 2026

Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com Nigeria

Sep 01, 2026
pulisher
Sep 01, 2026

Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating - Investing.com

Sep 01, 2026
pulisher
Aug 30, 2026

Rocket Pharmaceuticals (RCKT) Jumps 6.6% to $3.86 as Buyers Defend Key Support LevelGap Up Stocks - vinanet.vn

Aug 30, 2026
pulisher
Aug 29, 2026

Rocket Pharmaceuticals (RCKT) Surges 6.6% to $3.86 as Gene Therapy Stock Tests Key ResistanceJelly Roll Trade - careplusvn.com

Aug 29, 2026
pulisher
Aug 28, 2026

New Jersey's Rocket Pharma Strikes New Pay Deal For Its GC - Law360

Aug 28, 2026
pulisher
Aug 21, 2026

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - GuruFocus

Aug 21, 2026
pulisher
Aug 21, 2026

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Aug 21, 2026
pulisher
Aug 20, 2026

Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com - Investing.com South Africa

Aug 20, 2026

Rocket Pharmaceuticals Inc (RCKT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$114.14
price down icon 1.29%
$58.36
price up icon 0.24%
$36.57
price up icon 0.19%
$246.74
price down icon 2.89%
ONC ONC
$365.94
price up icon 0.18%
$205.26
price up icon 0.38%
大文字化:     |  ボリューム (24 時間):